All Updates

All Updates

icon
Filter
FDA approval
Signet Therapeutics receives IND approval from FDA for gastric cancer treatment
AI Drug Discovery
Jul 1, 2024
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
AI Drug Discovery

AI Drug Discovery

Jul 1, 2024

Signet Therapeutics receives IND approval from FDA for gastric cancer treatment

FDA approval

  • AI-based oncology therapy developer Signet Therapeutics has received FDA approval for its IND application for sigx1094, a targeted drug for diffuse gastric cancer (DGC). Following the approval, the company is prepared to commence Phase I clinical trials to assess the treatment's safety and efficacy against DGC and other advanced solid tumors.

  • Sigx1094 was developed using Signet's proprietary organoid disease model platform and AI in collaboration with AI-powered R&D platform company XtalPi. Organoids refer to 3D miniaturized versions of organs or tissues derived from stem cells. They can mimic an organ's key function, structure, and biological complexity, aiding in drug development and clinical trials. 

  • Signet Therapeutics focuses on developing targeted oncology therapeutics, leveraging advanced AI technology and disease models to enhance drug discovery and development processes. The company’s approach uses real-world cancer genomics data to create 3D organoid models, providing more clinically relevant data.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.